On Friday, Shares of InterCloud Systems, Inc. (NASDAQ:ICLD), skyrocketed 75.66% to $2.67.
InterCloud Systems, declared that it was awarded a professional services contract by a global telephone company to provide services around next-gen network upgrades in their central offices in California. The estimated value of the contract is $3 Million. This work is predictable to start right away with a majority of the work to take place during this calendar year.
Chairman and CEO Mark Munro stated, “We are excited about these new professional service projects. The continued influx of contracts such as these demonstrates our continued growth and the confidence we enjoy from fortune 100 customers.” Mark Munro added, ” InterCloud is uniquely positioned to assist our customers migrate from legacy IT and telecom infrastructure to the next generation networks, which will continue to be virtualized and orchestrated by platforms like our NFVGrid automation software. We look forward to this transition and will continue to develop our products to stay steps ahead of the competition.”
InterCloud Systems, Inc. provides end-to-end IT and network solutions to the telecommunications service provider and corporate enterprise markets through cloud platforms and professional services in the United States and internationally.
At the end of Friday’s trade, Shares of Nutrisystem, Inc. (NASDAQ:NTRI), jumped 22.05% to $23.25, hitting its highest level.
Nutrisystem, stated that the Company exceeded its formerly offered revenue, adjusted EBITDA, and earnings per share guidance for the first quarter 2015 and is raising its formerly offered outlook for the full year.
First Quarter 2015 Contrast to First Quarter 2014
- Revenue raised 12% to $137.2 million contrast to $122.2 million.
- Gross profit margin improved 310 basis points to 52.0% and gross profit raised 19% to $71.4 million.
- Adjusted EBITDA grew 146% to $8.0 million contrast to $3.2 million.
- Net income raised to $2.9 million contrast to $0.2 million.
- Earnings per share raised to $0.10 per share from $0.01 per share.
Nutrisystem, Inc., together with its auxiliaries, provides weight loss programs for women, men, and seniors in the United States. The company offers Nutrisystem program that comprises of about 150 portion-controlled items, which serve as the foundation of a low glycemic index diet.
Nektar Therapeutics (NASDAQ:NKTR), ended its last trade with 20.59% gain, and closed at $11.48.
Nektar Therapeutics, stated its financial results for the first quarter ended March 31, 2015.
Cash and investments in marketable securities at March 31, 2015 were $325.8 million as contrast to $262.8 million at December 31, 2014. Our cash and investments in marketable securities at March 31, 2015 comprises a $100.0 million milestone payment received from AstraZeneca in Q1 2015 for the first commercial sale of Movantik™(naloxegol) in the U.S.
Revenue for the first quarter of 2015 was $108.8 million as contrast to $19.8 million in the first quarter of 2014. The enhance in revenue in the first quarter of 2015 as contrast to the first quarter of 2014 is due to the recognition of $90.0 million of the $100.0 million milestone payment from AstraZeneca following the first commercial sale of Movantik in the U.S. Revenue also comprised of non-cash royalty revenue, related to our 2012 royalty monetization, of $4.0 million and $5.8 million in the three months ended March 31, 2015 and 2014, respectively. This non-cash royalty revenue is offset by non-cash interest expense.
Total operating costs and expenses for the first quarter of 2015 were $65.8 million as contrast to $56.2 million in the first quarter of 2014. Total operating costs and expenses raised primarily as a result of raised research and development (R&D) expense.
R&D expense in the first quarter of 2015 was $47.0 million as contrast to $38.3 million for the first quarter of 2014. R&D expense was higher in the first quarter of 2015 primarily due to the initiation of the Phase 3 efficacy study of NKTR-181 in patients with chronic low back pain. Additionally, R&D expense in the first quarter of 2015 comprised of costs related to the continued production of devices for the ongoing Phase 3 studies of Amikacin Inhale, the ongoing Phase 3 study of NKTR-102 in breast cancer, the ongoing Phase 1 study of NKTR-171, and IND enabling activities for NKTR-214 which will enter the clinic in 2015.
General and administrative expense was $10.3 million in the first quarter of 2015 as contrast to $9.9 million in the first quarter of 2014.
In Q1 2015, net income was $33.8 million, or $0.26 basic earnings per share. This contrast to a net loss of $46.2 million or ($0.37) basic loss per share in Q1 2014.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Finally, SkyWest Inc. (NASDAQ:SKYW), closed at $16.12, with 18.10% gain, hitting its highest level.
SkyWest, stated financial and operating results for the quarter ended March 31, 2015.
SkyWest generated $9.6 million of net income, or $0.18 per diluted share, for Q1 2015. This represents an after-tax improvement of $32.5 million from Q1 2014, which had a net loss of $(22.9) million, or $(0.44) per diluted share.
Q1 2015 Financial Highlights
- Pre-tax income raised $59 million from Q1 2014 primarily due to improved operating performance, additional flying contracts and improved recovery from weather disruptions.
- SkyWest generated $100 million in EBITDA in Q1 2015, contrast to $35 million in Q1 2014.
- Revenue comprised of improvements of $21 million from higher flight completion rates and $33 million from the additional E175 operations, improved contract rates from renewals and extensions and improved contract performance incentives. These improvements offered a noteworthy offset to the anticipated revenue decrease from a reduced fleet size and production.
- Operating expenses were down by $74 million contrast to Q1 2014, primarily driven by improved operating efficiencies and a net decrease in production.
SkyWest, Inc., through its auxiliaries, operates a regional airline in the United States. It provides planned passenger and air freight services with about 3,500 total daily departures to various destinations in the United States, Canada, Mexico, and the Caribbean.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
